Why the Midwest Dental expansion matters for DENTSPLY SIRONA
DENTSPLY SIRONA (XRAY) has extended its relationship with Midwest Dental, which will start distributing the company's technology portfolio across the United States from 1 November 2026. This moves the relationship beyond the historical consumables focus.
This shift gives DENTSPLY SIRONA wider reach for its digital dentistry tools through Midwest Dental's sales, service, and technical teams. For shareholders, the move highlights how management is aiming to get more clinics using its connected technology offerings.
The agreement is also one piece of a broader 2026 push. Management has now updated seven North American dealer relationships, aiming for broader coverage and easier customer access rather than relying on a single distribution route.
Recent trading tells a different story to the commercial push. DENTSPLY SIRONA's 1 day share price return of 1.76% sits against a 30 day share price decline of 20.93% and a 1 year total shareholder return fall of 27.86%. The expanded Midwest Dental deal lands while momentum has been fading over three and five year periods, with total shareholder returns down 69.32% and 83.05% respectively. Any change in sentiment is likely to hinge on whether this broader 2026 distribution reset starts to shift perceptions of future risk and opportunity.
Spot opportunities that rhyme with the DENTSPLY SIRONA story by scanning our hand picked list of 32 healthcare AI stocks .
So is the Midwest Dental expansion a sign that DENTSPLY SIRONA's business engine is quietly resetting, or is the share price slide a blunt verdict on sentiment that the current valuation now reflects?
Most Popular Narrative: 35.1% Undervalued
DENTSPLY SIRONA's most followed narrative pins fair value at $13.40, which sits well above the last close at $8.69 and frames the current slide as a valuation gap rather than a business collapse.
Active cost reduction programs, operational streamlining, and supply chain optimization are in progress. Management has indicated a stronger urgency to go "deeper and faster," potentially boosting EBITDA margin and cash flow generation through both lower SG&A and more efficient manufacturing.
Management's focus on closer customer relationships, clinician workflow enhancements, and proceduralization is expected to drive sales force effectiveness and bolster share in aesthetic and restorative segments, areas benefiting from heightened health awareness and the global trend toward elective and preventive dental procedures.
See why 10 investors see DENTSPLY SIRONA as 35% undervalued .
Result: Fair Value of $13.40 (UNDERVALUED)
Still, the narrative around DENTSPLY SIRONA only holds if tariff pressures ease and elective categories stop weakening; otherwise, margin and market share concerns stay front and center.
Find out about the key risks to this DENTSPLY SIRONA narrative .
Next Steps
Sentiment in this piece might feel mixed, yet decisions still come down to your own reading of the facts and time horizon. If you want to see what has investors optimistic, review the 3 key rewards
Looking for more DENTSPLY SIRONA style investment ideas?
If DENTSPLY SIRONA has sharpened your focus on valuation and risk, do not stop here. Broaden your watchlist with a few focused, data driven screens.
-
Target potential value gaps by scanning the 27 high quality undervalued stocks that currently pass tight quality and fundamentals checks.
-
Prioritise resilience first and stress test your watchlist against the 31 resilient stocks with low risk scores that score well on stability metrics.
-
Hunt for future leaders early by running the 20 high quality undiscovered gems before these businesses move onto everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include XRAY .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
